

## Recommendations for Pharma

## Throughout drug development process

- 1 Engage with payers alongside regulators as soon as the decision to include a digital endpoint is made
- 2 Prep to bridge knowledge gaps & requirements to demonstrate acceptability & value of digital endpoints to all stakeholders
- 3 Build your IEP before starting your clinical trials



## During digital endpoint selection/development

- 1 Validate & evaluate digital endpoints
- 2 Investigate relationship between digital measures & endpoints with long term outcomes & events
- 3 Include study design elements that allow for estimation of MCID
- **4** Engage early with national healthcare standards bodies, payers, & regulators
- 5 Develop evidence of acceptability & usefulness
- 6 Select endpoint(s) that are scalable & fit-for-purpose



- 1 Prioritize collection of confirmatory evidence that shows scalability of new evidence & the relationship to accepted endpoints in clinical development
- 2 Include outcomes that matter to payers in trials (e.g. medical cost usage, hospitalization)
- **3** Collect more RWE, in parallel with digital endpoints, earlier in clinical development

